Insulin resistance was associated with adverse clinical outcomes among patients with PCOS and normal weight undergoing ...

GLP-1 RAs are not linked to an increased risk for serious GI or hepatobiliary outcomes, compared with other diabetes medications.

An association exists between higher night-to-night sleep duration variation and increased risk for major cardiovascular disease events.

Providing immediate bedside hepatitis C virus (HCV) consultation at discharge from labor and delivery for women with HCV-affected pregnancies is associated with higher rates of treatment completion ...

Population aging is the largest contributor to the increasing burden of musculoskeletal (MSK) disorders in about one-third of countries.

In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and cardiometabolic outcomes.

This patient perspective entails a first-hand experience of fatphobia and weight-inclusive health care in the clinical setting.

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD), the cardiometabolic risk factors (CMRFs) of high blood pressure, glucose intolerance, and low high-density ...

Early on-treatment liver stiffness measurements predict reduced risk for liver-related events in patients with CHB receiving ...

Dapagliflozin significantly decreases risk for new-onset type 2 diabetes mellitus following myocardial infarction regardless of glycemic status or BMI.

Topline results were announced from a phase 3 trial investigating intranasal carbetocin for the treatment of hyperphagia in Prader-Willi syndrome.

The FDA has approved Bosaya and Aukelso, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.